Selective antagonism of NMDA receptors containing GluN2B subunits has proven to be effective in curbing the pathological roles of excitotoxicity in the progression of various disorders such as AD, PD, neuropathic pain, and depression [93,94]. Here, GRIN2B is linked to Parkinson disease.